Q4 2024 Earnings Call Transcript March 31, 2025 Cytosorbents Corporation beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.07. Operator: Good afternoon, ladies and gentleman ...

We are focused initially on the blood thinner, Brilinta, in patients undergoing coronary artery bypass ... Our product gross margin remained healthy at 71% reflecting the strength of our ...

We were focused initially on the blood thinner Berlinta in patients undergoing coronary artery bypass ... Our product gross margin remained healthy at 71%, reflecting the strength of our ...

That's because an abnormal gene from one parent overrides the normal gene from the other ... Hypercholesterolemia [HeFH] or premature coronary artery disease, the company is in the process ...

with a structurally (gross and histologically) normal heart at autopsy or negative diagnostic findings after survival. Notably, in the age group ≤35 years 7 of 14 confirmed diagnoses of coronary ...

Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott's investigational ...

Paradigm Shift in Cardiac Surgery: Key innovations The ELANA® Heart Bypass System will enable surgeons to perform the most state-of-the-art coronary artery bypass grafting (CABG) with arterial ...

The study, dubbed TECTONIC, is slated to enroll up to 335 people with coronary artery disease across the U.S. Abbott said the technology will build upon its current portfolio for managing heart ...

However, a new approach to determining risk and selecting a statin is the use of the coronary artery calcium (CAC) score which is determined by taking a low-radiation dose image of the heart using ...